New findings on psychedelics will be presented at Neuroscience 2023, the annual meeting of the Society for Neuroscience, on Tuesday, 14 November.
Psychedelic therapy company Sunstone Therapies has announced the start of its first study investigating multiple doses of psilocybin in the treatment of major depression disorder (MDD)...
A study from the Centre for Psychedelic Research at Imperial College London has shown that extended DMT IV infusions are safe and well tolerated.
Mind Medicine has confirmed it has completed enrollment of Study MMED007, its Phase 2a study evaluating repeated low-dose administration of MM-120 (LSD) for the treatment of...
Beckley Psytech has confirmed it has dosed the first patient in its international Phase 2b study of BPL-003 – a novel synthetic intranasal formulation of 5-MeO-DMT...
The Brain & Behavior Research Foundation has announced it is awarding $10.2 million in Young Investigator Grants including for projects investigating psychedelics.
Multiple studies have shown that ketamine is a fast acting treatment for depression, but a key issue with the studies is that many participants can tell...
Small Pharma has reported positive results from its study investigating the interaction of SSRIs and SPL026 – the company’s native DMT – in patients with Major...
Cybin Inc.
Results from the world’s largest study investigating the ‘naturalistic’ use of psilocybin outside of research settings have shown lasting therapeutic benefits.
